Moclobemid 1 A Pharma (Moclobemide)

Moclobemide, the active ingredient in Moclobemid 1 A Pharma, is a reversible monoamine oxidase inhibitor (MAOI) presented as an oral tablet for oral use. It treats major depressive disorder and social anxiety disorder in adult patients.

GNH USA supplies Moclobemid 1 A Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moclobemide is used to manage mood and anxiety disorders by increasing central monoamine levels.

Major depressive disorder: reduces depressive symptoms and improves overall mood. Social anxiety disorder: lessens anxiety in social situations and enhances functional performance. Depressive symptoms associated with other psychiatric conditions: provides adjunctive relief when standard therapies are insufficient.

Moclobemide may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea - Headache - Insomnia or somnolence - Dizziness - Dry mouth - Constipation

Serious or Rare Side Effects: - Hypertensive crisis, especially with tyramine‑rich foods - Serotonin syndrome when combined with other serotonergic agents - Severe liver injury - Life‑threatening skin reactions (e.g., Stevens‑Johnson syndrome) - Agranulocytosis - Emergence of suicidal thoughts or behaviors

Before prescribing Moclobemide, clinicians should consider several safety measures.

Assess hepatic function: evaluate liver enzymes prior to initiation. Monitor blood pressure: advise avoidance of tyramine‑rich foods to prevent hypertensive episodes. Screen psychiatric history: watch for worsening depression or suicidal ideation. Avoid abrupt discontinuation: taper under medical supervision to reduce withdrawal risk. Pregnancy and lactation: safety not established; use only if benefits outweigh potential risks. Store at ambient temperature: keep in the original container, protect from moisture and light.

Moclobemide interacts with several drug classes; some combinations must be avoided while others require close monitoring.

Major Interactions (Avoid): - Tyramine‑rich foods: risk of hypertensive crisis. - Selective serotonin reuptake inhibitors (SSRIs): potential serotonin syndrome. - Other MAO inhibitors: severe hypertension. - Sympathomimetic agents (e.g., phenylephrine): elevated blood pressure. - St. John’s wort: increased serotonin toxicity.

Moderate Interactions (Monitor Closely): - Tricyclic antidepressants: may amplify serotonergic effects. - Linezolid: risk of serotonin syndrome. - Meperidine: potential serotonin toxicity. - Decongestants (pseudoephedrine): may raise blood pressure. - Antihypertensives: possible reduction in therapeutic effect.